KRAS and neoplasm: They can cause mutations in genes crucially related to tumour suppressors (e.g., p53) and protooncogenes (e.g., KRAS, EGFR), contributing to the initiation of lung cancer by promoting activation of signalling pathways and genetic alterations involved in cell cycle malfunction, resistance to apoptosis, and tumour progression.